TAICHI: Taiwan Metabochip Consortium
The TAICHI consortium is a well-phenotyped East Asian sample set consisting of >20,000 Han Chinese subjects drawn from seven principal cohorts. The consortium’s main aim is to identify genetic determinants of atherosclerosis and diabetes related traits in East Asians and to fine map validated loci identified in other race/ethnic groups. The main U.S academic sites participating in the Tai Chi consortium include Stanford University School of Medicine; Hudson-Alpha Biotechnology Institute and Los Angeles Biomedical Research Institute at Harbor-UCLA. The main academic sites in Taiwan include National Health Research Institute (NHRI); National Taiwan University Hospital (NTUH); Taipei and Taichung Veteran’s General Hospitals (VGH) and Tri-Service General Hospital (TSGH). Qualitative/categorical traits include coronary artery disease (CAD) either clinically or angiographically defined, type 2 diabetes mellitus (DM), and hypertension. Additional diabetes related microvascular complications include either retinopathy (DR) and/or nephropathy (DN). Cardiac specific quantitative traits other than those related to atherosclerosis include blood troponin levels, EKG derived intervals such as QT length, and cardiac imaging derived measures including LVH and pericardial fat.